Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Julissa Gonzalez Villegas

University of Puerto Rico, USA

Title: Surface derivatization of zirconium phosphate nanoplatelets: Potential nanocarrier of doxorubicin anticancer drug

Biography

Biography: Julissa Gonzalez Villegas

Abstract

Surface modification of doxorubicin anticancer drug (DOX) intercalated zirconium phosphate (ZrP) nanoparticles (DOX@ZrP) is proposed to improve the potential of this drug delivery system for cancer therapy. The surface of DOX@ZrP nanoparticles was modified with an amorphous layer of Zr(IV) followed by modification with monomethyl-polyethylene glycol-monophosphate (m-PEG-PO3) to increase the DOX@ZrP biocompatibility. 31P{1H}MAS NMR data shows a new peak at -26 ppm corresponding to the PO43- groups coordinated with Zr(IV) on the surface. m-PEG-PO3/Zr(IV)/DOX@ZrP spectra shows no additional resonance centered at d of -22.6 ppm generated by proton-phosphorous cross polarization indicating no partial PEG intercalation in the interlaminar space. Simulated body fluid (SBF) was used to determine the in vitro release of DOX from DOX@ZrP, Zr(IV)/DOX@ZrP, and m-PEG-PO3/ Zr(IV)/DOX@ZrP.  MTS cell viability assay reveal that m-PEG-PO3/ Zr(IV)/DOX@ZrP exhibited a 20% increase in the toxicity comparing with free DOX when PC3 cells are exposed for 48 h.  m-PEG-PO3 polymer coating of DOX@ZrP nanoparticles promise to have a strong impact on the targeting, distribution and degradation of the nanoparticles under physiological environment that should result in a more efficient chemotherapy agent than free doxorubicin.